Join the Irritable Bowel Syndrome group to help and get support from people like you.
Irritable Bowel Syndrome News
Related terms: IBS, Spastic colon
IgG-Guided Elimination Diet Beneficial for Irritable Bowel Syndrome
THURSDAY, Feb. 20, 2025 – Patients with irritable bowel syndrome (IBS) on an immunoglobulin (Ig)G-guided elimination diet are more likely to have a 30 percent or greater reduction in abdominal pain...
Blood Test Could Guide Better Diet For Irritable Bowel Syndrome
WEDNESDAY, Feb. 19, 2025 – A blood test can help people with irritable bowel syndrome cut out specific trigger foods most likely to worsen their condition, a new study suggests. About 60% of IBS...
High-Fiber Diets Linked to Gut Health & Fewer Harmful Bacteria
WEDNESDAY, Jan. 22, 2025 – Could eating more fiber be the key to a healthier gut? Research suggests the answer is yes. The findings, published recently in the journal Nature Microbiology, analyzed...
ACG: Hormone Therapy Tied to Higher Risk for New Irritable Bowel Syndrome
THURSDAY, Oct. 31, 2024 – Hormone replacement therapy (HRT) is associated with an increased risk for developing irritable bowel syndrome (IBS) in postmenopausal women, according to a study presented...
Odds of IBS, Functional Dyspepsia Increased After Acute Gastroenteritis Episode
WEDNESDAY, July 17, 2024 – A considerable proportion of individuals experiencing acute gastroenteritis develop postinfection irritable bowel syndrome (PI-IBS) and postinfection functional dyspepsia...
Rates of Severe Multiple Drug Intolerance Syndrome Up in Fibromyalgia, IBS
THURSDAY, May 23, 2024 – Patients with fibromyalgia and irritable bowel syndrome (IBS) have increased rates of severe multiple drug intolerance syndrome (MDIS), according to a study published in the...
FDA Approves Ibsrela (tenapanor) for the Treatment of Irritable Bowel Syndrome with Constipation
FREMONT, Calif., Sept. 12, 2019 /PRNewswire/ – Ardelyx, Inc. today announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the...
FDA Approves the Reintroduction of Zelnorm (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in Women Under 65
LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ – US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, has received approval from the U.S. Food and Drug...
Synergy Pharmaceuticals Announces FDA Approval of Trulance (plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
NEW YORK--(BUSINESS WIRE) January 25, 2018 – Synergy Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Trulance (plecanatide) 3 mg tablet for the...
FDA Medwatch Alert: Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder
ISSUE: FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review...
FDA Medwatch Alert: Hyoscyamine sulfate 0.125mg by Virtus Pharmaceuticals: Recall - Superpotent and Subpotent Test Results
ISSUE: Virtus Pharmaceuticals Opco II, LLC (Virtus) is voluntarily recalling seven batches of Hyoscyamine sulfate (0.125mg) to the consumer level which include the tablet, sublingual, and orally...
FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)
LAVAL, Quebec, May 27, 2015 /PRNewswire/ – Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received...
FDA Approves Viberzi (eluxadoline) for Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults
DUBLIN, May 27, 2015 /PRNewswire/ – Actavis plc (NYSE: ACT) announced today that Viberzi (eluxadoline) was approved by the Food and Drug Administration (FDA) as a twice-daily, oral treatment for...
FDA Approves Linzess to Treat Certain Cases of Irritable Bowel Syndrome and Constipation
August 30,2012 – The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C)...
FDA Medwatch Alert: Zelnorm (tegaserod maleate)
[Posted 03/30/2007] FDA notified healthcare professionals and patients that Novartis has agreed to discontinue marketing Zelnorm, a drug used for the short-term treatment of women with irritable...
Further information
Related condition support groups
Related drug support groups
escitalopram, amitriptyline, venlafaxine, MiraLax, Linzess, nortriptyline, dicyclomine, Metamucil, Bentyl, view more... clomipramine, doxepin, Imodium, cholestyramine, Amitiza, Xifaxan